Methods of treating hemophilia or von willebrand disease with p-selectin

Abstract

The present invention identifies P-selectin as a modulator of hemostasis. Accordingly, the present invention relates to methods for the identification and use of modulators of P-selectin activity as modulators of hemostasis. The invention also relates to methods and compositions for the diagnosis and treatment of hemostatic disorders, including, but not limited to, hemorrhagic disorders and thrombotic disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hemostatic conditions, and for the identification of subjects exhibiting a predisposition to such conditions. In addition, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of a hemostatic or vascular disorders, and for monitoring the efficacy of compounds in clinical trials.

1. A method for treating hemophilia or von Willebrand's disease in a subject, said method comprising administering to said subject an inducer of P-selectin activity selected from the group consisting of a soluble P-selectin polypeptide and a P-selectin fusion protein, such that the hemophilia or von Willebrand's disease is treated or prevented. 
     
     
       2. The method of  claim 1 , wherein said hemophilia is hemophilia A. 
     
     
       3. The method of  claim 1 , wherein said hemophilia is hemophilia B. 
     
     
       4. The method of  claim 1 , wherein the inducer of P-selectin activity increases the level of soluble P-selectin polypeptide in the plasma of the subject. 
     
     
       5. The method of  claim 1 , wherein the inducer of P-selectin activity is a fusion protein. 
     
     
       6. The method of  claim 1 , wherein the P-selectin fusion protein comprises a soluble P-selectin polypeptide operatively linked to an immunoglobulin. 
     
     
       7. The method of  claim 6 , wherein the immunoglobulin is a human IgG 1, and the Fc region of the immunoglobulin is fused to the C-terminus of at least one soluble P-selectin polypeptide.